University of Alberta

Pence, Inc.

S.p.i. Synthetic Peptides Incorporated

Kok K Lee

Robert S Hodges

Randall Thomas Irvin

William Paranchych

Sastry A Parimi

Peter C Doig

Wah Yau Wong

Hasmukh B Sheth

Lei Yu

Dick E Zoutman

A method of treating Candida albicans infection is disclosed. In one embodiment, for treatment of oral or vaginal infection, the treatment is by topical application of a composition of conjugates that are each composed of a carrier structure and multiple .beta.GalNac(1-4).beta.Gal moieties attached to the structure. In another embodiment, for treatment of systemic infection, the treatment is by parenteral administration of a humanized form of a mouse monoclonal antibody produced by mouse hybridoma cell line Fm16 or cell line PK99H.

Method of treating candida infection

Treatment and diagnosis of P. aeruginosa infection or colonization is achieved in accordance with this invention by the discovery of a polypeptide which is smaller than the naturally occurring P. aeruginosa pillin protein. The pure polypeptide comprises at least one amino acid residue sequence containing about twelve amino acid residues and up to about twenty amino acid residues that define a sequence capable of immunologically mimicking an antigenic determinant cite of P. aeruginosa pilin. This amino acid residue sequence can repeat as a unit one or more times in the same polypeptide molecule. More than one of such repeating units and more than one repeating unit of the same type can be present in a single polypeptide molecule. The polypeptides act an antigens or immunogens and antibodies may be raised to the immunogens and a vaccine prepared suitable for the prevention of P. aeruginosa infection.

Synthetic Pseudomonas aeruginosa pilin peptide vaccine

A peptide having a sequence corresponding to a C-terminal portion of the Pseudomonas aeruginosa pilin protein is disclosed. The peptide is cross-reactive with surface peptides present in certain bacterial and fungal microorganisms, and is effective in inhibiting binding of such organisms to target epithelial cells. The peptide may also be employed in a vaccine composition, for producing immunity against such cross-reactive microorganisms. Also disclosed are methods of preparing peptides which are cross-reactive with the P. aeruginosa pilin peptide, and chimeric monoclonal antibodies immunoreactive with the pilin peptide.

Pseudomonas peptide composition and method

Synthetic pseudomonas aeruginosa pilin peptide vaccine and method of use

Growing community of inventors

Edmonton, Canada

Kok K Lee